Supernus Pharma Stock Analysis, Valuation (NASDAQ:SUPN)

Add to My Stocks
$44.6 $0.1 (0.22%) SUPN stock closing price Mar 19, 2018 (Closing)
Watch Robo Advisor Video of SUPN Stock Analysis
Supernus Pharma
Updated on : Mar 19, 2018
previous close
SUPN 44.7 (0%)
S&P 500 2752 (0%)
Closing Price On: Mar 16, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Generic Drugs
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Long Term Growth
5 Year CAGR:
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Recent Growth
Long Term Growth
Operating Margins
Net Margins
PE Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Supernus Pharma Stock Analysis

254 5 2

Take a look at Amigobulls Supernus Pharma stock analysis video. Our SUPN analysis video highlights revenue and profit trends along with other important metrics such as valuation to find what makes the stock attractive.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Supernus Pharmaceuticals Inc Stock Rating 4/5

We at Amigobulls use various financial measures including profit margins, revenue growth and dividends for SUPN stock analysis. Supernus Pharma valuation forms a crucial part of our stock analysis. Our Supernus Pharma stock rating is based on company's fundamentals like balance sheet risk and cash flow position.

Should you buy SUPN stock?

  • Supernus Pharma sales grew by 41.8% year on year in 2017 Q4.
  • The company saw a significant growth in revenue with a 5 year CAGR of 189.7%.
  • Supernus Pharma's average operating margin of 32.9% was exceptional.
  • LTM Net margins were good at 19% for Supernus Pharma.
  • Supernus Pharma's return on invested capital of 36.3% is good.
  • Return On Equity (ROE) which is a measure of the company's profitability, looks great for Supernus Pharma at 25%.
  • Supernus Pharma has a healthy FCF (Free Cash Flow) margin of 40.2%.

Should you sell SUPN stock?

  • Trading at a PE ratio of 36, SUPN stock is overvalued in comparison to industry average multiple of 23.7.

Comments on this video and Supernus Pharma stock

Amigobulls Supernus Pharma stock analysis helps in evaluating the financial statements of a company to arrive at a conclusion about the fair value of SUPN stock. The fundamentals of a company are vital to identify long-term investment opportunities.

Among the financials of the company, Supernus Pharma revenue growth along with the profit or net income give a clear picture of the financial health. One can also combine technical analysis and fundamental analysis to get a holistic picture about SUPN stock.